Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Naval Daver

Leukemia · MD Anderson Cancer Center

View

Dr. Daniel Pollyea

Leukemia · CU Anschutz Medical Campus

View

Dr. Jessica Altman

Leukemia · Northwestern Medicine

View

Dr. Shella Saint Fleur-Lominy

Leukemia · UMSOM

View

Dr. Azra Raza

Leukemia · CUIMC

View

Dr. Molly Imgruet

Leukemia · Stanford

View

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Saad Usmani

Myeloma · MSK

View

Dr. Hope Rugo

Breast Oncology · City of Hope

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    KMDr. Kamal Menghrajani
    Leading Voice

    Dr. Kamal Menghrajani

    Hematology & Oncology · Leukemia
    Massachusetts General Hospital
    drkamalmenghrajani
    New York, NY

    Research

    Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia

    2025

    Via Cell Stem Cell

    Research

    High-risk and silent clonal hematopoietic genotypes in patients with nonhematologic cancer

    2024

    Via Blood Advances

    Research

    Acute Myeloid Leukemia Presenting as Common Colds: An Uncommon Consideration

    2024

    Via Cureus

    Research

    Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia

    2024

    Via Nature Genetics

    Research

    Targetable treatment resistance in thyroid cancer with clonal hematopoiesis

    2024

    Via bioRxiv (preprint)

    Research

    Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination

    2023

    Via Molecular Cell

    Research

    Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors

    2023

    Via JCO Precision Oncology

    Research

    Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML

    2022

    Via Blood Advances

    Research

    Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia

    2022

    Via American Journal of Hematology

    Research

    Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis

    2021

    Via Nature Communications

    Research

    The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy

    2021

    Via American Journal of Hematology

    Research

    Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

    2021

    Via Blood Advances

    Research

    Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant

    2021

    Via Leukemia & Lymphoma

    Research

    Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

    2020

    Via Nature Medicine

    Research

    Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study

    2019

    Via Haematologica